hyperbilirubinemia. Neonatal jaundice from other and unspecified causes
Conditions
Interventions
Intervention 1: The mother and neonate received Alhagi pseudalhagi 25% cocentration solution, 30 cc and 1cc/kg, respectively, every 8 hours as well as phototherapy until the serum level of bilirubin d
Treatment - Drugs
Treatment - Other
The mother and neonate received Alhagi pseudalhagi 25% cocentration solution, 30 cc and 1cc/kg, respectively, every 8 hours as well as phototherapy until the serum level of bilirubin decreased to the
The mother only received Alhagi pseudalhagi 25% cocentration solution, 30 cc every 8 hours as well as phototherapy for the neonates until the serum level of bilirubin decreased to the normal level.
In the control group, neither mother nor neonate received the solution. The neonates only received phototherapy until the serum level of bilirubin decreased to the normal level.
The neonate only received Alhagi pseudalhagi 25% cocentration solution, 1 cc/kg, every 8 hours as well as phototherapy until the serum level of bilirubin decreased to the normal level.
Sponsors
Shahrekord University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Years to 1 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Signing informed consent by parents, total serum bilirubin between 14 and 20 mg/dL, presence of Non hemolytic hyperbilirubinemia, presence of indirect hyperbilirubinemia, hyperbilirubinemia which starts between the third and tenth days after birth, term infant, (Gestational age 42-37 weeks), birth weight 4-5/2 Kg, exclusive breast feeding, Ability of mother to attend the neonate’s bedside, no congenital anomaly, no sepsis, history of asphyxia, or traumatic delivery, no cephalohematoma, no history of neonatal jaundice, no previous treatment for jaundice, any other treatments or hospitalization, no other treatment with antibiotic or other drugs Exclusion criteria: discharge for any reason before bilirubin less than 12mg/dl, need to other drugs during treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of bilirubin. Timepoint: Baseline and then daily during the study. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospital stay. Timepoint: During hospital stay. Method of measurement: The number of days that neonate is hospitalized. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed